Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

Open access

Abstract

Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double-blind, randomized, placebo-controlled, crossover design in 28 healthy subjects (14 women, 14 men) who underwent five 25 h sessions and received placebo, LSD (100 and 200 µg), and psilocybin (15 and 30 mg). Test days were separated by at least 10 days. Outcome measures included self-rating scales for subjective effects, autonomic effects, adverse effects, effect durations, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol, and oxytocin, and pharmacokinetics. The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects. The 15 mg psilocybin dose produced clearly weaker subjective effects compared with both doses of LSD and 30 mg psilocybin. The 200 µg dose of LSD induced higher ratings of ego-dissolution, impairments in control and cognition, and anxiety than the 100 µg dose. The 200 µg dose of LSD increased only ratings of ineffability significantly more than 30 mg psilocybin. LSD at both doses had clearly longer effect durations than psilocybin. Psilocybin increased blood pressure more than LSD, whereas LSD increased heart rate more than psilocybin. However, both LSD and psilocybin showed comparable cardiostimulant properties, assessed by the rate-pressure product. Both LSD and psilocybin had dose-proportional pharmacokinetics and first-order elimination. Both doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively very similar subjective effects, indicating that alterations of mind that are induced by LSD and psilocybin do not differ beyond the effect duration. Any differences between LSD and psilocybin are dose-dependent rather than substance-dependent. However, LSD and psilocybin differentially increased heart rate and blood pressure. These results may assist with dose finding for future psychedelic research. Trial registration: ClinicalTrials.gov identifier: NCT03604744

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41386-022-01297-2

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Acute alterations of mind on the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. Psilocybin at 30 mg produced alterations of mind that were nominally similar to 100 µg LSD and not significantly different from either 100 or 200 µg LSD. LSD at 100 and 200 µg significantly differed only in the “Anxious Ego Dissolution” total score and the “impaired control and cognition” and “anxiety” subscales. Effects of the 15 mg psilocybin dose were clearly lower than 100 and 200 µg LSD and 30 mg psilocybin on most subscales. Placebo scores were too low for visualization. The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 28 subjects. Statistics are shown in Supplementary Table S1.
Fig. 1 Acute alterations of mind on the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. Psilocybin at 30 mg produced alterations of mind that were nominally similar to 100 µg LSD and not significantly different from either 100 or 200 µg LSD. LSD at 100 and 200 µg significantly differed only in the “Anxious Ego Dissolution” total score and the “impaired control and cognition” and “anxiety” subscales. Effects of the 15 mg psilocybin dose were clearly lower than 100 and 200 µg LSD and 30 mg psilocybin on most subscales. Placebo scores were too low for visualization. The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 28 subjects. Statistics are shown in Supplementary Table S1.CC BY · PubMed Central
Fig. 2 Acute subjective effects induced by lysergic acid diethylamide (LSD) and psilocybin over time on the Visual Analog Scale (VAS). LSD (100 or 200 µg), psilocybin (15 or 30 mg), or placebo was administered at t = 0 h. Generally, the LSD doses of 100 µg and 200 µg and psilocybin dose of 30 mg produced comparable subjective effects on the VASs “any drug effect,” “good drug effect,” “bad drug effect,” “drug liking,” “feeling high,” “feeling stimulated,” and “fear.” Only the VAS “ego dissolution” showed a significant difference between 100 and 200 µg LSD. The high 30 mg psilocybin dose produced maximal subjective effects that were comparable to 100 and 200 µg LSD, with no significant differences on any of the VASs. The 30 mg psilocybin dose produced significantly greater peak responses than the 15 mg psilocybin dose on the VAS “any drug effect,” “good drug effect,” “feeling stimulated,” and “ego dissolution.” The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 28 subjects. The corresponding maximal responses and statistics are shown in Supplementary Table S3.
Fig. 2 Acute subjective effects induced by lysergic acid diethylamide (LSD) and psilocybin over time on the Visual Analog Scale (VAS). LSD (100 or 200 µg), psilocybin (15 or 30 mg), or placebo was administered at t = 0 h. Generally, the LSD doses of 100 µg and 200 µg and psilocybin dose of 30 mg produced comparable subjective effects on the VASs “any drug effect,” “good drug effect,” “bad drug effect,” “drug liking,” “feeling high,” “feeling stimulated,” and “fear.” Only the VAS “ego dissolution” showed a significant difference between 100 and 200 µg LSD. The high 30 mg psilocybin dose produced maximal subjective effects that were comparable to 100 and 200 µg LSD, with no significant differences on any of the VASs. The 30 mg psilocybin dose produced significantly greater peak responses than the 15 mg psilocybin dose on the VAS “any drug effect,” “good drug effect,” “feeling stimulated,” and “ego dissolution.” The data are expressed as the mean ± SEM percentage of maximally possible scale scores in 28 subjects. The corresponding maximal responses and statistics are shown in Supplementary Table S3.CC BY · PubMed Central
Fig. 3 Acute autonomic effects of lysergic acid diethylamide (LSD) and psilocybin over time. The 100 and 200 µg doses of lysergic acid diethylamide (LSD) only moderately increased blood pressure compared with placebo, whereas 15 and 30 mg psilocybin induced more pronounced increases in blood pressure. The 100 and 200 µg doses of LSD markedly increased heart rate, whereas only the higher 30 mg dose of psilocybin induced a moderate increase in heart rate compared with placebo. Both the 100 and 200 μg LSD doses and the 15 mg psilocybin dose increased body temperature moderately and similarly, whereas 30 mg psilocybin induced a more pronounced increase in body temperature compared with all other conditions. LSD (100 or 200 µg), psilocybin (15 or 30 mg), or placebo was administered at t = 0 h. The data are expressed as the mean ± SEM in 28 subjects. Maximal effects and statistics are shown in Supplementary Table S5.
Fig. 3 Acute autonomic effects of lysergic acid diethylamide (LSD) and psilocybin over time. The 100 and 200 µg doses of lysergic acid diethylamide (LSD) only moderately increased blood pressure compared with placebo, whereas 15 and 30 mg psilocybin induced more pronounced increases in blood pressure. The 100 and 200 µg doses of LSD markedly increased heart rate, whereas only the higher 30 mg dose of psilocybin induced a moderate increase in heart rate compared with placebo. Both the 100 and 200 μg LSD doses and the 15 mg psilocybin dose increased body temperature moderately and similarly, whereas 30 mg psilocybin induced a more pronounced increase in body temperature compared with all other conditions. LSD (100 or 200 µg), psilocybin (15 or 30 mg), or placebo was administered at t = 0 h. The data are expressed as the mean ± SEM in 28 subjects. Maximal effects and statistics are shown in Supplementary Table S5.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 226

Metadata

Authors
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., Varghese, N., Eckert, A., & Liechti, M. E.
Affiliations
University of Basel (CH)
Corresponding author
Liechti, Matthias E.
Venue
Neuropsychopharmacology
Published
2022-02-25
Volume
47
Issue
6
Pages
1180-1187
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W4214649547
Cited by
226
References
50
Citations by year
2026: 41 · 2025: 61 · 2024: 67 · 2023: 38 · 2022: 19
FWCI
42.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • edoc (University of Basel) (acceptedVersion)
  • edoc (University of Basel)
Funders
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (32003B_185111)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
Keywords
lysergic acid diethylamide, psilocybin, autonomic effects, dose equivalence, ego dissolution, ineffability, anxiety, heart rate, blood pressure, rate-pressure product, pharmacokinetics, brain-derived neurotrophic factor, prolactin, cortisol, oxytocin
MeSH terms
Double-Blind Method, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Psilocybin, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. https://app.cochat.ai/papers/10.1038/s41386-022-01297-2
The paper
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., Varghese, N., Eckert, A., & Liechti, M. E. (2022). Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01297-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.